Sincerest congratulations to #TBCPartners Capstan Therapeutics and Seaport Therapeutics, who last night were named as two of this year’s #Endpoints11! This award is a culmination of each company’s dedication to advancing some of the most exciting and innovative science in the field. We are proud to partner with organizations like Capstan and Seaport who are raising the bar for patients. Endpoints News
Last night in Boston, the Endpoints News team unveiled the Endpoints 11 — our picks for the most exciting biotech startups of 2024. This year’s list includes several artificial intelligence startups trying to reinvent drug R&D, though doing so with very different approaches. It highlights the growth of China’s biotech industry, despite the country’s tensions with the US. Four of the winners are taking new approaches to huge disease categories including inflammation and immunology, obesity and neuroscience. And others are working on advanced technologies for rare ailments, operating at the forefront of editing biology. Congratulations to: Lifordi Immunotherapeutics, Inc., Mirador Therapeutics, Formation Bio, Xaira Therapeutics, Medilink International, Iambic Therapeutics, Ascidian Therapeutics, Capstan Therapeutics, Seaport Therapeutics, Metsera, Cardurion Pharmaceuticals Read our profiles of this year’s winners here.